Moffitt Cancer Center researchers have developed the first patient-reported outcome (PRO) measure for patients receiving radionuclide therapy (RNT) to guide treatment and improve quality of care. Lisa M. Gudenkauf, PhD, and colleagues published their findings in The Journal of Nuclear Medicine. ...
Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Implementing a genetic testing model for prostate cancer patients can improve detection rates for actionable mutations.
A study sought to assess organoids and short-term ex vivo cultures of prostate cancer.
Researchers developed the first validated risk model for discerning personalized prostate cancer risks.
A risk score can predict prostate cancer in men of African ancestry.
A greater family history of prostate cancer is associated with a lower risk of mortality.
Dr. Jacqueline Brown talks about current challenges and advances in phenotypic precision medicine and treatment strategies.
Advertisement
Video Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Norman E Sharpless, MD, University of North Carolina School of Medicine, will present the keynote session.
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.
The event will feature world-class science and new and innovative findings in the study of GU malignancies.
At the ASTRO 2022 meeting, several authors presented abstracts on postprostatectomy radiation that are worth reviewing.
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
Advertisement
Advertisement
Trending
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
